Clinical Trial Update: KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on KX2-391 in patients with advanced solid tumors or lymphoma that did not respond to prior treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Lymphoproliferative Disorder
• Small Intestine Cancer

Drugs mentioned

• KX2-391

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Lymphoma, Lymphoproliferative Disorder | Phase 1 | Status: COMPLETED